<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460419</url>
  </required_header>
  <id_info>
    <org_study_id>2015029</org_study_id>
    <nct_id>NCT02460419</nct_id>
  </id_info>
  <brief_title>Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital of Shantou University Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomised, phase 3 study is to evaluate the survival benefit of&#xD;
      maintenance capecitabine plus best supportive care versus best supportive care for metastatic&#xD;
      nasopharyngeal carcinoma patients after disease controlled with TPC palliative chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Firstly diagnosed metastatic nasopharyngeal carcinoma patients will receive 4-6 cycles of&#xD;
      palliative chemotherapy with taxol,cisplatin and capecitabine. After disease controlled, they&#xD;
      will be randomly assigned to maintenance capecitabine plus best supportive care(BSC) or BSC&#xD;
      alone. The primary end point is progression-free survival, the secondary end points are&#xD;
      overall survival, duration of response, objective response rate, adverse effects and quality&#xD;
      of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>up to 6 years</time_frame>
    <description>the time from randomization to the progression of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 6 years</time_frame>
    <description>the time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>up to 6 years</time_frame>
    <description>the time from the date of the first cycle of chemotherapy to the progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 6 years</time_frame>
    <description>CR, PR and SD rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>up to 6 years</time_frame>
    <description>chemotherapy side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life of the patients during the Maintenance Capecitabine and/or Best Supportive Care</measure>
    <time_frame>up to 6 years</time_frame>
    <description>evaluate with FACT-H&amp;N every 3 months after randomiztion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>maintenance capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maintenance capecitabine plus best supportive care(BSC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>best supportive care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best supportive care and following-up every 6-8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>maintenance capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best supportive care (BSC)</intervention_name>
    <description>Best supportive care and following-up every 6-8 weeks</description>
    <arm_group_label>best supportive care</arm_group_label>
    <arm_group_label>maintenance capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Firstly diagnosed metastatic nasopharyngeal carcinoma patients&#xD;
&#xD;
          -  Disease controlled after 4-6 cycles of palliative chemotherapy with taxol,cisplatin&#xD;
             and capecitabine&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
          -  Life expectation at least 12 weeks&#xD;
&#xD;
          -  No systemic chemotherapy within 6 months, except for induction chemotherapy or&#xD;
             concurrent chemotherapy&#xD;
&#xD;
          -  With at least one measurable lesion&#xD;
&#xD;
          -  Enough blood test&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sever heart disease&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Sever infection&#xD;
&#xD;
          -  Brain metastasis, except received radical therapy 6 months ago and stable in 4 weeks&#xD;
&#xD;
          -  Allogeneic organ transplantation&#xD;
&#xD;
          -  Malignancy other than nasopharyngeal carcinoma, except:cervical carcinoma in situ,&#xD;
             cured basal cell carcinoma,bladder cancer of Ta,Tis or T1, or any cured cancer for at&#xD;
             least 3 years&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Difficulty in swallowing&#xD;
&#xD;
          -  Received other test drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Guo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SunYat-senU</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jin Y, Shi YX, Cai XY, Xia XY, Cai YC, Cao Y, Zhang WD, Hu WH, Jiang WQ. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012 Oct;138(10):1717-25. Epub 2012 Jun 10. Erratum in: J Cancer Res Clin Oncol. 2015 Apr;141(4):767.</citation>
    <PMID>22684794</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Yiu HH, Seetalarom K, Ng AW, Kurnianda J, Shotelersuk K, Krishnan G, Hong RL, Yang MH, Wang CH, Sze WK, Ng WT. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head Neck. 2012 Sep;34(9):1225-30. doi: 10.1002/hed.21884. Epub 2011 Nov 11.</citation>
    <PMID>22076785</PMID>
  </reference>
  <reference>
    <citation>Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, Tay MH, Poon D, Tan EH. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 2008 Sep 15;113(6):1332-7. doi: 10.1002/cncr.23687.</citation>
    <PMID>18615622</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>XIANG YANQUN</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>metastasis</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

